Fc-Dependent Mechanisms of Antibody-Mediated Killing (R21 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save

Next deadline: Oct 16, 2021

Later deadlines: Nov 16, 2021, Jan 7, 2022

Grant amount: Up to US $275,000

Fields of work: Allergies & Allergic Diseases Immune System Diseases

Applicant type: Organizations

Funding uses: Clinical Biomedical

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

This Funding Opportunity Announcement (FOA) invites R21 applications for studies that address knowledge gaps in mechanisms of Fc-dependent, antibody-mediated killing of infected cells or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. More specifically, the purpose of this FOA is to promote innovative and exploratory research to elucidate mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), and to promote development of tools, technologies, and animal models to facilitate identification and evaluation of cytotoxic killing mechanisms mediated by human antibodies in vivo.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

This page was last reviewed October 08, 2018 and last updated October 08, 2018